Protagonist Therapeutics (NASDAQ:PTGX) Insider Arturo Md Molina Sells 5,000 Shares

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) insider Arturo Md Molina sold 5,000 shares of the business’s stock in a transaction dated Tuesday, January 27th. The stock was sold at an average price of $82.00, for a total value of $410,000.00. Following the sale, the insider directly owned 84,115 shares of the company’s stock, valued at $6,897,430. This represents a 5.61% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Arturo Md Molina also recently made the following trade(s):

• On Friday, January 23rd, Arturo Md Molina sold 13,151 shares of Protagonist Therapeutics stock. The shares were sold at an average price of $82.42, for a total transaction of $1,083,905.42.
• On Tuesday, January 20th, Arturo Md Molina sold 9,514 shares of Protagonist Therapeutics stock. The stock was sold at an average price of $82.48, for a total transaction of $784,714.72.

Protagonist Therapeutics Trading Up 0.9%

Shares of PTGX traded up $0.78 on Tuesday, reaching $83.08. 507,797 shares of the company’s stock were exchanged, compared to its average volume of 747,674. The business has a 50 day moving average price of $86.49 and a two-hundred day moving average price of $72.41. Protagonist Therapeutics, Inc. has a 12 month low of $33.70 and a 12 month high of $96.54. The stock has a market capitalization of $5.19 billion, a P/E ratio of 134.00 and a beta of 2.26.

Protagonist Therapeutics (NASDAQ:PTGX) last released its earnings results on Thursday, November 6th. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.03). The business had revenue of $4.71 million for the quarter, compared to analyst estimates of $5.41 million. Protagonist Therapeutics had a return on equity of 6.86% and a net margin of 21.94%. Equities research analysts predict that Protagonist Therapeutics, Inc. will post 2.43 EPS for the current year.

Hedge Funds Weigh In On Protagonist Therapeutics

A number of large investors have recently added to or reduced their stakes in PTGX. Royal Bank of Canada raised its stake in shares of Protagonist Therapeutics by 30.6% during the 1st quarter. Royal Bank of Canada now owns 9,964 shares of the company’s stock worth $482,000 after purchasing an additional 2,334 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Protagonist Therapeutics by 0.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,403 shares of the company’s stock worth $1,810,000 after buying an additional 348 shares during the last quarter. Millennium Management LLC raised its position in Protagonist Therapeutics by 283.6% during the first quarter. Millennium Management LLC now owns 134,269 shares of the company’s stock worth $6,493,000 after acquiring an additional 99,269 shares in the last quarter. State of Alaska Department of Revenue lifted its stake in Protagonist Therapeutics by 11.8% in the second quarter. State of Alaska Department of Revenue now owns 36,906 shares of the company’s stock valued at $2,039,000 after acquiring an additional 3,883 shares during the last quarter. Finally, Precision Wealth Strategies LLC acquired a new stake in Protagonist Therapeutics in the second quarter valued at $793,000. Institutional investors own 98.63% of the company’s stock.

Wall Street Analysts Forecast Growth

PTGX has been the topic of several analyst reports. JPMorgan Chase & Co. increased their target price on Protagonist Therapeutics from $68.00 to $81.00 and gave the company an “overweight” rating in a research note on Friday, November 7th. Wedbush upped their price target on Protagonist Therapeutics from $70.00 to $86.00 and gave the company an “outperform” rating in a research note on Tuesday, October 28th. BTIG Research reissued a “buy” rating and set a $82.00 price objective on shares of Protagonist Therapeutics in a research note on Tuesday, October 28th. Citigroup upped their target price on shares of Protagonist Therapeutics from $98.00 to $115.00 and gave the company a “buy” rating in a research note on Monday, December 8th. Finally, Citizens Jmp increased their target price on shares of Protagonist Therapeutics from $69.00 to $102.00 and gave the stock a “market outperform” rating in a report on Friday, November 7th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Protagonist Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $86.77.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral ?4?7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.